Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4376478 | 0.86 | POLB (0.35) | POLBGAAIDO1HSP90AA1MAPK1 | |
| SCHEMBL4446548 | 0.76 | CYP19A1 (0.35) | POLBKDM4EHPGD | |
| Carbon Monoxide SCHEMBL9452220 | 0.73 | HSP90AA1 (0.38) | POLBHSP90AA1MAPK1SMN1; SMN2KDM4E | |
| SCHEMBL31273832 | 0.69 | IDO1 (0.41) | GAAIDO1KDM4E | |
| SCHEMBL37706 | 0.66 | POLB (0.35) | POLBGAAIDO1HSP90AA1MAPK1 | |
| SCHEMBL15072746 | 0.66 | POLB (0.35) | POLBGAAIDO1HSP90AA1MAPK1 | |
| SCHEMBL67450 | 0.65 | IDO1 (0.34) | POLBGAAIDO1SMN1; SMN2KDM4E | |
| SCHEMBL6130827 | 0.64 | GAA (0.37) | POLBGAAIDO1HSP90AA1MAPK1 | |
| SCHEMBL3276201 | 0.64 | HSP90AA1 (0.38) | POLBGAAHSP90AA1MAPK1SMN1; SMN2 | |
| SCHEMBL12474127 | 0.64 | POLB (0.41) | POLBGAAHSP90AA1MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117858964-A | Flow cell | 因美纳有限公司 | 2024-04-09 | — | — | CN | disclosed |
| US-20230365584-A1 | HETEROCYCLIC PERICONDENSED CDC7 KINASE INHIBITORS FOR THE TREATMENT OF CANCER | SCHRÖDINGER, INC. | 2023-11-16 | — | — | US | disclosed |
| CN-116490507-A | Heterocyclic condensation CDC7 kinase inhibitors for the treatment of cancer | 薛定谔公司 | 2023-07-25 | — | — | CN | disclosed |
| EP-4211140-A1 | HETEROCYCLIC PERICONDENSED CDC7 KINASE INHIBITORS FOR THE TREATMENT OF CANCER | Schrödinger, Inc. (US) | 2023-07-19 | — | — | EP | disclosed |
| WO-2022055963-A1 | HETEROCYCLIC PERICONDENSED CDC7 KINASE INHIBITORS FOR THE TREATMENT OF CANCER | SCHRÖDINGER, INC. (US) | 2022-03-17 | — | — | WO | disclosed |
| EP-3458459-A1 | MACROCYCLIC INDOLE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2019-03-27 | — | — | EP | disclosed |
| EP-3004123-B1 | RUTHENIUM-BASED COMPLEXES, THEIR PREPARATION AND USE AS CATALYSTS | ARLANXEO DEUTSCHLAND GMBH (DE) | 2018-03-28 | — | — | EP | disclosed |
| WO-2017198341-A1 | MACROCYCLIC INDOLE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2017-11-23 | — | — | WO | disclosed |
| EP-2961737-B1 | NOVEL CARBOXAMIDE COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2017-07-26 | — | — | EP | disclosed |
| EP-1803761-B1 | Ring-opened copolymer, hydrogenated ring-opened copolymer, process for producing thereof, and compositions | ZEON CORP (JP) | 2016-04-27 | — | — | EP | disclosed |
| EP-2961737-A1 | NOVEL CARBOXAMIDE COMPOUNDS | Syngenta Participations AG (CH) | 2016-01-06 | — | — | EP | disclosed |
| WO-2015009656-A1 | SULFONATED POLYETHYLENE | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2015-01-22 | — | — | WO | disclosed |
| WO-2014131572-A1 | NOVEL CARBOXAMIDE COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2014-09-04 | — | — | WO | disclosed |
| EP-2590791-A2 | LABELED CONTAINERS AND PROCESSES FOR PRODUCING LABELED CONTAINERS | Nestec S.A. (CH) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012005761-A2 | LABELED CONTAINERS AND PROCESSES FOR PRODUCING LABELED CONTAINERS | NESTEC S.A. (CH) | 2012-01-12 | — | — | WO | disclosed |
| EP-1915345-B1 | FLUORO SUBSTITUTED 2-OXO AZEPAN DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-12-22 | — | — | EP | disclosed |
| US-7084222-B2 | Ruthenium complexes, process for preparation thereof, and processes for producing open-ring polymer of cycloolefins and hydrogenation products thereof by using the complex as catalyst | ZEON CORPORATION (JP) | 2006-08-01 | — | — | US | disclosed |
| EP-1682521-A1 | MACROCYCLIC LACTAMS AND PHARMACEUTICAL USE THEREOF | Novartis AG (CH) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005049585-A1 | MACROCYCLIC LACTAMS AND PHARMACEUTICAL USE THEREOF | NOVARTIS AG (CH) | 2005-06-02 | — | — | WO | disclosed |
| EP-1197509-A1 | PROCESS FOR PRODUCING HYDROGENATED RING-OPENING POLYMERIZATION POLYMER OF CYCLOOLEFIN | Nippon Zeon Co., Ltd. (JP) | 2002-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365584-A1 | HETEROCYCLIC PERICONDENSED CDC7 KINASE INHIBITORS FOR THE TREATMENT OF CANCER | CDC7, BUB1B, CDK7 | POLB 1983/4885GAA 2784/4885IDO1 4546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.